Current oncologic applications of radiofrequency ablation therapies

Table 2 Studies reporting survival after use of radiofrequency ablation for colorectal liver metastases

Ref.	Patients (tumors) n	Median tumor size (cm)	Extrahepatic disease		Chemotherapy	Method	% complete ablation	Local recurrence	Overall survival
									1 yr	3 yr	5 yr
Abdalla et al[26]	57 (110) for RFA	2.5	No	NR	0	NR	9% for RFA	NR	37% for RFA43% for HR + RFA		NR
	190 for HR						5% for HR + RFA		73% for HR
	101 for RFA + HR						2% for HR
Siperstein et al[27]	234 (665)	3.9 (mean)	Yes		80% before RFA	L	NR	NR	NR	20%2	18%2
Park et al[28]	30 for RFA	2.0 for RFA	No		73% after RFA	P	NR	23% for RFA	NR	NR	19%2 for RF1
	59 for HR	3.1 for HR			81% after HR			2% for HR			48%2 for HR
Abitabile et al[54]	47 (147)	2	Yes		After RFA	O, P	97%	9% for overall	88%1	57%1	21%1
								0%-5% for < 3 cm
Gillams et al[55]	167 (167)	3.9 (mean)	Yes		80% before RFA	P	NR	14.00%	99%1	58%1	30%1
									91%2	28%2	25%2
Jakobs et al[56]	68 (183)	2.28 (mean)	No		78% parallel or after	P	NR	18.00%	96%2	71%2
Machi et al[57]	100 (507)	3.0 (mean)	NR			O, L, P		7%	90%	42%	31%
Schindera et al[58]	14 (20)	1.8	No		NR	P	89%	15%	72%2	60%2	NR
White et al[59]	30 (56)	3.0 (0.8-7)	No		36% before, 50% after	P	89%	17%	75%2	45%2	NR
Solbiati et al[60]	117 (179)	2.6	Yes		72% parallel	P	98%	39%	93%2	46%2	NR

¹Calculated from time of diagnosis of liver metastases;

²Calculated after radiofrequency ablation (RFA) treatment of liver metastases. P, L, O: Percutaneous, laparoscopic, open; NR: Not reported; HR: Hazard ratio.